Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 12/20 | 0.51 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273560 | 1.00 | ADRB2 (0.51) | ADRB2PDK2CTSDFFAR1CA1 | |
| SCHEMBL3626479 | 0.92 | ADRB2 (0.44) | ADRB2PDK2 | |
| SCHEMBL3626476 | 0.92 | ADRB2 (0.44) | ADRB2PDK2 | |
| SCHEMBL5580686 | 0.87 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL5580683 | 0.87 | ADRB2 (0.38) | ADRB2 | |
| SCHEMBL13807616 | 0.85 | ADRB2 (0.37) | ADRB2 | |
| SCHEMBL3625089 | 0.84 | ADRB2 (0.59) | ADRB2 | |
| SCHEMBL3625091 | 0.84 | ADRB2 (0.59) | ADRB2 | |
| SCHEMBL4276530 | 0.83 | ADRB2 (0.40) | ADRB2 | |
| SCHEMBL4276537 | 0.83 | ADRB2 (0.40) | ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-7547731-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2009-06-16 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | PFIZER INC | 2008-08-28 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-7241810-B2 | Formamide derivatives for the treatment of diseases | PFIZER INC (US) | 2007-07-10 | — | — | US | disclosed |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | PFIZER LIMITED (GB) | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207689-A1 | Formamide Derivatives For The Treatment of Diseases | FH, FAH, HRH4 | ADRB2 751/4885PDK2 685/4885CTSD 816/4885 |
| US-20050215590-A1 | Formamide derivatives for the treatment of diseases | FH, FAH, HRH4 | ADRB2 751/4885PDK2 685/4885CTSD 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.